Massachusetts General Hospital CRS (MGH CRS)*

Boston, Massachusetts 02114

2 studies enrolling now · 24 studies all time

What they study most

CMV, Cardiovascular Diseases, Cytomegalovirus, Cytomegalovirus Infections, HIV, HIV Infection, HIV Infections, HIV-1, HIV-1-infection, Hepatitis B, Hepatitis B Virus, Hepatitis C

Studies at this site

• Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 — Recruiting now
• Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Paused
• The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE — Running, not enrolling
• Study of Tecovirimat for Human Mpox Virus — Stopped early
• A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection — Starting soon
• Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) — Completed
• Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy — Paused
• Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults — Completed
• B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B — Completed
• A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. — Stopped early
• Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors — Completed
• Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy — Completed
• Pharmacokinetics and Safety of SAR441236 — Stopped early
• Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy — Withdrawn before enrolling
• HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study — Completed
• Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) — Completed
• Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) — Completed
• Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women — Completed
• Optimizing Treatment for Treatment-Experienced, HIV-Infected People — Completed
• Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection — Completed
• Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects — Completed
• Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women — Completed
• Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load — Completed
• Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients — Completed